May 5, 2011 by staff
WebMD reports Tradjenta (linagliptin) is a DPP-4 inhibitor, placing it in the same class as Januvia and Onglyza. Like other DPP-4 inhibitors, Tradjenta can be taken with other treatment options for diabetes, such as metformin.
“This approval offers another treatment option for millions of Americans with type 2 diabetes,” Mary Parks, MD, director of FDA’s division of metabolism and endocrinology products, said in a news release. “It is effective when used alone or when added to existing treatment regimens.”
Tradjenta blocks a chemical marker in intestinal cells, which stimulates the release of insulin after a meal. This maintains the levels of blood sugar to rise, keeping the user safe from the associated drop in blood sugar (hypoglycemia).
Common side effects include Tradjenta have respiratory infection, stuffy or runny nose, sore throat, muscle pain and headache. Boehringer Ingelheim and Lilly market the drug.
Please feel free to send if you have any questions regarding this post , you can contact on
Disclaimer: The views expressed on this site are that of the authors and not necessarily that of U.S.S.POST.